The research further examines and provides data on the market by type, application and geography interspersed with illustrations and other graphical representations. The market analysis not only determines the attractiveness of the industry but also the evolving challenges and opportunities and their association with the weaknesses and strengths of prominent market leaders. Other factors taken into consideration when studying the industry include profitability, manufacturing capability, distribution channels and industry cost structure and major success factors. The global immunotherapy drugs market is projected to be reach USD 365.57 Billion by 2027, according to a current analysis by Emergen Research.
Read
more@ https://www.emergenresearch.com/industry-report/immunotherapy-drugs-market
Key Highlights of Report
In
September 2020, Immunomedics, Inc. was acquired by Gilead Sciences, Inc. The
deal will extend Gilead's product portfolio; also, the acquisition represented
an essential step in the plan of Gilead to build a broad and inclusive oncology
pipeline.
Due
to the advantages of monoclonal antibodies like adaptive and highly
reproductive, the monoclonal antibodies segment is anticipated to lead the
immunotherapy drugs market, expanding at a rate of 12.3% during the forecast
period.
In
the immunotherapy drugs market, the cancer segment is expected to hold the
largest market share during the forecast period. The increasing incidence of
cancer, rise in research activity in this field, and insurance availability for
oncology immunotherapies are factors driving the segment.
Due
to the increasing spending on immunotherapy by hospitals and rising requirement
for innovative treatments, the hospitals segment is projected to lead the
global immunotherapy drugs market during the forecast period.
North
America is expected to lead the global market for immunotherapy drugs during
the forecast period, due to the escalating incidence of cancer and autoimmune
disorders, increasing demand for improved cancer therapies, increasing amount
of clearance by the Food and Drug Administration, and favorable reimbursement
scenario.
Key market participants
include Sanofi
S.A., F. Hoffmann-La Roche AG, Merck & Co., Inc., AstraZeneca plc, BioNTech
SE, Gilead Sciences, Inc., Incyte Corporation, bluebird bio, Inc., Genmab A/S,
and Bayer AG
Drug Type Outlook
(Revenue, USD Billion; 2017–2027)
Checkpoint
Inhibitors
Monoclonal
Antibodies
Vaccines
Interleukins
Interferons
Alpha and Beta
Others
Therapeutic Area Outlook
(Revenue, USD Billion; 2017–2027)
Infectious
Diseases
Autoimmune
& Inflammatory Diseases
Cancer
Others
End-user Outlook
(Revenue, USD Billion; 2017–2027)
Clinics
Research
Centers
Hospitals
Others
Regional Scope- North America; Europe; Asia Pacific; Central & South America; MEA
Table of Content
Chapter 1. Market Synopsis
1.1. Immunotherapy Drugs Market Definition
1.2. Immunotherapy Drugs Market Research
Scope & Premise
1.3. Immunotherapy Drugs Market Methodology
1.4. Immunotherapy Drugs Market Estimation
Technique
Chapter 2. Executive Summary
2.1. Summary Snapshot, 2019-2027
Chapter 3. Indicative Metrics
Chapter 4. Immunotherapy Drugs
Market Segmentation & Impact Analysis
4.1. Immunotherapy Drugs Market Product
Segmentation Analysis
4.2. Industrial Outlook
4.2.1. Market indicators analysis
4.2.2. Market drivers analysis
Chapter 5. Immunotherapy Drugs
Market By Method Insights & Trends
Chapter 6. Immunotherapy Drugs
Market By End-Use Insights & Trends
Chapter 7. Immunotherapy Drugs
Market By Application Insights & Trends
Chapter 8. Immunotherapy Drugs
Market Regional Outlook
Chapter 9. Immunotherapy Drugs
Market Competitive Landscape
Chapter 10. Company Profiles
Continue…
No comments:
Post a Comment